Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Action: Physiological Effects

DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones

Nathalie Saint-Lu, Charles Burdet, Frédérique Sablier-Gallis, Tanguy Corbel, Agathe Nevière, Sakina Sayah-Jeanne, Mark Pulse, William Weiss, Stéphanie Ferreira, Antoine Andremont, France Mentré, Jean de Gunzburg
Nathalie Saint-Lu
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Burdet
bUniversité de Paris, IAME, INSERM, Paris, France
cAP-HP, Bichat Hospital, Department of Epidemiology, Biostatistics, and Clinical Research, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frédérique Sablier-Gallis
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanguy Corbel
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agathe Nevière
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sakina Sayah-Jeanne
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Pulse
dUNT Health Science Center, Fort Worth, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Weiss
dUNT Health Science Center, Fort Worth, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphanie Ferreira
eGenoScreen, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Andremont
bUniversité de Paris, IAME, INSERM, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
France Mentré
bUniversité de Paris, IAME, INSERM, Paris, France
cAP-HP, Bichat Hospital, Department of Epidemiology, Biostatistics, and Clinical Research, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean de Gunzburg
aDa Volterra, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean de Gunzburg
DOI: 10.1128/AAC.01196-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Fluoroquinolone treatments induce dysbiosis of the intestinal microbiota, resulting in loss of resistance to colonization by exogenous bacteria such as Clostridioides difficile that may cause severe diarrhea in humans and lethal infection in hamsters. We show here that DAV131A, a charcoal-based adsorbent, decreases the intestinal levels of the fluoroquinolone antibiotics levofloxacin and ciprofloxacin in hamsters, protects their intestinal microbiota, and prevents lethal infection by C. difficile.

INTRODUCTION

Fluoroquinolone (FQ) antibiotics have significant biliary excretion rates, resulting in high intestinal concentrations that impact the intestinal microbiota (1) and are thus risk factors for Clostridioides difficile infections (CDI) (2–5), the leading cause of health care-associated infections (6). To prevent this risk, Da Volterra has developed DAV132, an adsorbent delivered to the late ileum that sequesters antibiotic residues and preserves the microbiota, as demonstrated in human phase 1 clinical studies (7, 8). To assess whether it would prevent CDI, we initiated studies in hamsters, showing that DAV131A, a rodent-adapted version of DAV132, was able to prevent CDI in animals treated with clindamycin or the fluoroquinolone moxifloxacin (MXF) (9, 10). Here, we have extended MXF observations to levofloxacin (LVX) and ciprofloxacin (CIP), which are more frequently used than MXF (Da Volterra, unpublished data).

Male Golden Syrian hamsters were infected orally on day 3 (D3) with 104 spores of C. difficile strain UNT103-1 (VA-11, REA J strain obtained from Curtis Donskey, Ohio VA Medical Centre) and received 110 mg/kg LVX subcutaneously or 100 mg/kg CIP intraperitoneally daily from D1 to D5, the lowest doses resulting in 100% mortality (data not shown).

Groups of 10 LVX- or CIP-treated animals were randomly assigned to receive oral DAV131A twice daily from D1 to D8 at unit doses of 0 (placebo), 100, 200, 300, 600, 900, or 1,350 mg/kg (this last dose was only applied with CIP because free fecal concentrations were higher than with LVX and MXF [Table 1 and reference 10]). Further controls received antibiotic placebo (saline) together with DAV131A placebo, or either antibiotic (LVX or CIP) together with DAV131A placebo, but were not infected. Fecal free antibiotic concentrations were measured by bioassay (11) using the indicator strains K. pneumoniae ATCC 10031 for LVX and B. subtilis ATCC 6633 for CIP. Data below the limit of quantification (0.19 μg/g for LVX and 1.04 μg/g for CIP) were imputed to half of the limit of quantification. Fecal microbiota composition was analyzed by 16S rRNA genes sequencing as described previously (10), and sequence data were submitted to the NCBI database under accession number PRJNA478191.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Mortality rates and fecal concentrations of active antibiotic at D3 according to treatment groups in the levofloxacin and ciprofloxacin studiesa

Mortality rates at D16 were compared using a global Fisher exact test, with the Benjamini-Hochberg’s correction method for multiple testing, when necessary. Fecal free antibiotic concentrations and microbiota diversity indices were compared using the Kruskal-Wallis test. For α-diversity indices, analyses were performed on changes between D3 and D0. In case of significant difference, post hoc comparisons were performed using nonparametric Wilcoxon tests with Benjamini-Hochberg’s correction.

The link between bacterial diversity and mortality by D16 was analyzed on the pooled data from the two studies presented here, together with those from a previously published study with the same design but exposing hamsters to 30 mg/kg MXF (10). Death probability was estimated for all diversity indices using the areas under the receiving operator curve (AUROCs) and the corresponding 95% confidence intervals.

Data are presented as the number of observations (n) or the median (minimum, maximum). All tests were two sided with a type I error of 0.05. All analyses were performed using R software v3.5.1.

LVX or CIP treatments resulted in 100% mortality at D16, after C. difficile inoculation (Fig. 1A and Table 1). Animals with LVX died within 3 days of inoculation and within 4 to 9 days with CIP, in parallel with high counts of fecal C. difficile (Fig. 1B). Protection by DAV131A was dose dependent (Table 1 and Fig. 1), following the dose-dependent decrease in fecal antibiotic concentrations (significant from 200 mg/kg DAV131A; Fig. 1C and Table 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Survival rate (A), C. difficile counts (B), and free fecal antibiotic concentrations at D3 (C) in animals treated with LVX (left) and CIP (right) according to treatment group. In the “ABX/XXX” notation used in the legend, ABX is the antibiotic, and “XXX” is the unit dose of DAV131A (n = 10 for all groups except for CIP/600 group where n = 9). For the C. difficile counts, the mean and error bars representing the standard deviations are shown. For antibiotic concentrations, the boxes present the 25th and 75th percentiles, and the horizontal black bar reports the median value, while the whiskers indicate the 10th and 90th percentiles, and the outliers are also shown. Red asterisks represent adjusted P values of Wilcoxon tests comparing each group treated by antibiotic and DAV131A to the group treated by antibiotic alone (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

Antibiotics induced a severe dysbiosis, more pronounced with LVX that CIP. Increasing amounts of DAV131A enabled a dose-dependent protection, as measured by changes in α- and β-diversity between D3 and D0 (Fig. 2 and Table 2; see Tables S1A and B in the supplemental material). However, protection of the microbiota was not complete, as further attested by a principal coordinate analysis of microbiota diversity evolution over time (Fig. S1). Surviving animals had a modest decrease in α-diversity and an increase in β-diversity. Strikingly, these changes were significantly larger in animals that developed CDI (Fig. 3; see Tables S2 and 3).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Change of the Shannon index (α-diversity) (A) and unweighted UniFrac distance (β-diversity) (B) between D0 and D3 in animals treated with LVX (left) and CIP (right) according to the dose of DAV131A in each treatment group. The boxes present the 25th and 75th percentiles, and the horizontal black bar reports the median value, while the whiskers indicate the 10th and 90th percentiles, and the outliers are also shown. Asterisks represent adjusted P values of Wilcoxon tests comparing each group treated by antibiotic and DAV131A to the group treated by antibiotic alone (red stars) or to the untreated control group (gray star) (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Change between D0 and D3 of the Shannon index and unweighted UniFrac distances according to treatment groups in the LVX and CIP studiesa

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Change of the Shannon index (α-diversity) (A) and unweighted UniFrac distance (β-diversity) (B) between D0 and D3 in animals treated with LVX (left) and CIP (right) according to survival or death measured at the end of the study (D16). Colored circles indicate the dose of DAV131A received by each animal. The boxes present the 25th and 75th percentiles, and the horizontal black bar reports the median value, while the whiskers indicate the 10th and 90th percentiles. Red asterisks represent P values of the Wilcoxon tests for the comparison of animal fates (***, P < 0.001; ****, P < 0.0001).

To further assess how variations in diversity indices predicted D16 mortality, we pooled the data from these studies with those from a previous study (10) performed with MXF (Table 3 and see Table S4) and computed the AUROCs for each diversity index. For all, values close to or >0.8 were highly predictive of the outcome. Logistic models relating the mortality rate to the variations from D0 of the two most predictive diversity indices, the Shannon index, and unweighted UniFrac distances (Fig. 4), showed that, regardless of the FQs tested, changes from baseline in intestinal diversity around the time of C. difficile inoculation was a strong predictor of mortality.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3

Changes in microbiota diversity between D0 and D3a

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

Logistic models of mortality according to the change of Shannon index (A) (P < 10−15) and unweighted UniFrac distance (B) (P < 10−15) between D0 and D3 after pooling data from antibiotic-treated animals in the two studies performed with LVX and CIP, together with a previously published study with MXF (10). Red bars represent the mortality rates and their 95% confidence intervals of deciles of the observed diversity indices. The shaded areas represent the 95% confidence interval of the predicted probability of death.

Altogether, the major result of this study is that DAV131A lowered the level of fecal antibiotics and spared the animals by limiting dysbiosis. Full protection from lethal CDI was obtained with all FQs at relatively close DAV131A doses (200 mg/kg for MXF [10] and 300 mg/kg for LVX and CIP [this study]), although fecal antibiotics were still very high (94.6 [43.0, 162.1], 20.5 [11.1, 51.0], and 64.4 [10.1, 151.5] μg/g feces for MXF, LVX, and CIP, respectively) and dysbiosis was still present (a drop of the Shannon index by approximately 1 U and an increase in the unweighted UniFrac index of 0.55 to 0.70 U). Thus, the second major result of this study is that full protection of the microbiota from FQ-induced dysbiosis was not necessary for the prevention of CDI in hamsters.

However, DAV131A maintained the balance between the main bacterial groups (such as Firmicutes and Bacteroidetes at the phylum level and Ruminococcaceae and Lachnospiraceae at the family level, Fig. S2). Possibly more importantly, DAV131A limited the loss of microbiota diversity during antibiotic treatments, supporting the hypothesis that CDI prevention was due more to the maintenance of complex bacterial communities than to the presence of particular bacterial groups.

That free fecal antibiotic concentrations in hamsters mimicked rather well those in humans (8, 12, 13) suggests the relevance of transposing the preventative effect of DAV131A on antibiotic-induced CDI in hamsters to humans treated with DAV132, the human-targeted version of DAV131A which is currently in clinical development (8).

ACKNOWLEDGMENTS

N.S.-L., F.S.-G., S.S.-J., A.A., F.M., and J.D.G. designed the research. N.S.-L., T.C., M.P., and W.W. performed the research. S.F., T.C., and A.N. performed the metagenomic analysis. A.N. performed the statistical analysis of the data. J.D.G., A.A., C.B., F.M., T.C., and N.S.-L. wrote the paper. All authors agreed on the final version of the manuscript.

N.S.-L., F.S.-G., T.C., A.N., and S.S.-J. are employees of the Da Volterra Company. C.B., A.A., F.M., and J.D.G. are consultants for the Da Volterra Company.

This study was supported by Da Volterra, Paris, France.

FOOTNOTES

    • Received 12 June 2019.
    • Returned for modification 28 July 2019.
    • Accepted 8 October 2019.
    • Accepted manuscript posted online 21 October 2019.
  • Supplemental material is available online only.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. de Lastours V,
    2. Fantin B
    . 2015. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiol 10:1241–1255. doi:10.2217/fmb.15.40.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Brown KA,
    2. Khanafer N,
    3. Daneman N,
    4. Fisman DN
    . 2013. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57:2326–2332. doi:10.1128/AAC.02176-12.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Deshpande A,
    2. Pasupuleti V,
    3. Thota P,
    4. Pant C,
    5. Rolston DDK,
    6. Sferra TJ,
    7. Hernandez AV,
    8. Donskey CJ
    . 2013. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68:1951–1961. doi:10.1093/jac/dkt129.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Slimings C,
    2. Riley TV
    . 2014. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:881–891. doi:10.1093/jac/dkt477.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Vardakas KZ,
    2. Trigkidis KK,
    3. Boukouvala E,
    4. Falagas ME
    . 2016. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 48:1. doi:10.1016/j.ijantimicag.2016.03.008.
    OpenUrlCrossRef
  6. 6.↵
    1. Lessa FC,
    2. Mu Y,
    3. Bamberg WM,
    4. Beldavs ZG,
    5. Dumyati GK,
    6. Dunn JR,
    7. Farley MM,
    8. Holzbauer SM,
    9. Meek JI,
    10. Phipps EC,
    11. Wilson LE,
    12. Winston LG,
    13. Cohen JA,
    14. Limbago BM,
    15. Fridkin SK,
    16. Gerding DN,
    17. McDonald LC
    . 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825–834. doi:10.1056/NEJMoa1408913.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. de Gunzburg J,
    2. Ducher A,
    3. Modess C,
    4. Wegner D,
    5. Oswald S,
    6. Dressman J,
    7. Augustin V,
    8. Feger C,
    9. Andremont A,
    10. Weitschies W,
    11. Siegmund W
    . 2015. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: a proof of concept study in healthy subjects. J Clin Pharmacol 55:10–16. doi:10.1002/jcph.359.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. de Gunzburg J,
    2. Ghozlane A,
    3. Ducher A,
    4. Le Chatelier E,
    5. Duval X,
    6. Ruppé E,
    7. Armand-Lefevre L,
    8. Sablier-Gallis F,
    9. Burdet C,
    10. Alavoine L,
    11. Chachaty E,
    12. Augustin V,
    13. Varastet M,
    14. Levenez F,
    15. Kennedy S,
    16. Pons N,
    17. Mentré F,
    18. Andremont A
    . 2018. Protection of the human gut microbiome from antibiotics. J Infect Dis 217:628–636. doi:10.1093/infdis/jix604.
    OpenUrlCrossRef
  9. 9.↵
    1. Burdet C,
    2. Sayah-Jeanne S,
    3. Nguyen TT,
    4. Miossec C,
    5. Saint-Lu N,
    6. Pulse M,
    7. Weiss W,
    8. Andremont A,
    9. Mentré F,
    10. de Gunzburg J
    . 2017. Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agents Chemother 61:e00543-17. doi:10.1128/AAC.00543-17.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Burdet C,
    2. Sayah-Jeanne S,
    3. Nguyen TT,
    4. Hugon P,
    5. Sablier-Gallis F,
    6. Saint-Lu N,
    7. Corbel T,
    8. Ferreira S,
    9. Pulse M,
    10. Weiss W,
    11. Andremont A,
    12. Mentré F,
    13. de Gunzburg J
    . 2018. Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection. Antimicrob Agents Chemother 62. doi:10.1128/AAC.00925-18.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kitzis MD
    . 2010. Antibiotic assay. In Antibiogram, p 75–78. ASM Press, Washington, DC.
  12. 12.↵
    1. Edlund C,
    2. Sjöstedt S,
    3. Nord CE
    . 1997. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 29:383–386. doi:10.3109/00365549709011835.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Rashid M-U,
    2. Weintraub A,
    3. Nord CE
    . 2015. Development of antimicrobial resistance in the normal anaerobic microbiota during one year after administration of clindamycin or ciprofloxacin. Anaerobe 31:72–77. doi:10.1016/j.anaerobe.2014.10.004.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones
Nathalie Saint-Lu, Charles Burdet, Frédérique Sablier-Gallis, Tanguy Corbel, Agathe Nevière, Sakina Sayah-Jeanne, Mark Pulse, William Weiss, Stéphanie Ferreira, Antoine Andremont, France Mentré, Jean de Gunzburg
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01196-19; DOI: 10.1128/AAC.01196-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones
Nathalie Saint-Lu, Charles Burdet, Frédérique Sablier-Gallis, Tanguy Corbel, Agathe Nevière, Sakina Sayah-Jeanne, Mark Pulse, William Weiss, Stéphanie Ferreira, Antoine Andremont, France Mentré, Jean de Gunzburg
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01196-19; DOI: 10.1128/AAC.01196-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Clostridioides difficile infection
antibiotics
dysbiosis
fluoroquinolones
hamster animal model
prevention

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596